A new study has shown that HIV-infected women do not use statins as recommended by the most recent guidelines. Control of blood lipid levels to prevent heart disease is especially important in HIV-positive women, and they may also benefit from the potential anti-inflammatory effects of statins, as described in an article published in AIDS Patient Care and STDs, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
The article is available on AIDS Patient Care and STDs.
In the article entitled “Underutilization of Statins When Indicated in HIV-Seropositive and Seronegative Women,” Jonathan Todd, PhD, University of North Carolina, Chapel Hill and a national team of coauthors evaluated the use of statins by both HIV-infected and HIV-uninfected women in whom their use is indicated.
Statin use five years after indicated was low for both groups of women, with a rate of 38% for HIV-infected women. New guidelines for statin use released in 2013 increased the percentage of HIV-infected women for whom statin use is recommended from 16% to 45%.
“Despite the fact that HIV-infected individuals in the U.S. may have greater contact with healthcare providers than uninfected individuals of the same age, that is not reflected in consideration of their cardiac health,” says editor in chief Jeffrey Laurence, MD, professor of medicine at Weill Cornell Medical College in New York, NY. “This is clearly an important message as a major impediment to reaching a normal lifespan for HIV-positive individuals may be acceleration of disorders associated with aging, particularly cardiovascular disease.”
